Pneumagen

Saint Andrews, United Kingdom

Pneumagen develops glycan targeted carbohydrate binding modules (CBMs) for respiratory tract infections ) and cancer.

$10.0M raised

Jun 2023

Venture - Series Unknown

Top Investors

Scottish EnterpriseEquity GapEsperante VenturesThairm BioScottish Investment Bank

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Pneumagen raised?

Pneumagen has raised $10.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in June 2023.

Who are Pneumagen's investors?

Pneumagen's investors include Scottish Enterprise, Equity Gap, Esperante Ventures, Thairm Bio, Scottish Investment Bank.

Where is Pneumagen headquartered?

Pneumagen is headquartered in Saint Andrews, United Kingdom.

What does Pneumagen do?

Pneumagen develops glycan targeted carbohydrate binding modules (CBMs) for respiratory tract infections ) and cancer.

What stage is Pneumagen at?

Pneumagen is at the Venture - Series Unknown stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated June 1, 2023.

MLA

"Pneumagen — Funding & Investors." VCBacked, June 1, 2023, https://www.vcbacked.co/company/pneumagen. Accessed July 1, 2026.

APA

VCBacked. (2023). Pneumagen — Funding & Investors. Retrieved July 1, 2026, from https://www.vcbacked.co/company/pneumagen

Wikipedia (cite web)

{{cite web |title=Pneumagen — Funding & Investors |url=https://www.vcbacked.co/company/pneumagen |website=VCBacked |access-date=July 1, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated June 1, 2023.